These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 32466169

  • 21. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 22. Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells.
    Refolo MG, Lippolis C, Carella N, Cavallini A, Messa C, D'Alessandro R.
    Int J Mol Sci; 2018 May 19; 19(5):. PubMed ID: 29783729
    [Abstract] [Full Text] [Related]

  • 23. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T, Bellio M, Gentilin E, Molè D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, Degli Uberti E, Zatelli MC.
    Endocr Relat Cancer; 2013 Aug 19; 20(4):463-75. PubMed ID: 23653462
    [Abstract] [Full Text] [Related]

  • 24. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    Neoplasia; 2014 Jan 19; 16(1):43-72. PubMed ID: 24563619
    [Abstract] [Full Text] [Related]

  • 25. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, Wang J, Li B, Hu Y, Dong B, Shen L, Ji J, Gao J, Zhang X.
    Cell Death Dis; 2018 Jan 26; 9(2):123. PubMed ID: 29374144
    [Abstract] [Full Text] [Related]

  • 26. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W, Liu X, Zhang Y, Li A, Xie Y, Zhou S, Song L, Xu R, Ma Y, Cai S, Tang X.
    Biomed Res Int; 2021 Jan 26; 2021():5556306. PubMed ID: 33987439
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Calero R, Morchon E, Martinez-Argudo I, Serrano R.
    Cancer Lett; 2017 Oct 10; 406():1-11. PubMed ID: 28774796
    [Abstract] [Full Text] [Related]

  • 29. The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.
    Yin Y, Sui C, Meng F, Ma P, Jiang Y.
    Lipids Health Dis; 2017 May 03; 16(1):87. PubMed ID: 28468627
    [Abstract] [Full Text] [Related]

  • 30. Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer.
    Liu X, Xu W, Li L, Zhang Z, Lu M, Xia X.
    Int J Med Sci; 2024 May 03; 21(10):1814-1823. PubMed ID: 39113885
    [Abstract] [Full Text] [Related]

  • 31. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 03; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.
    Mol Cancer; 2012 Nov 20; 11():85. PubMed ID: 23167739
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ, Hsu SM, Chien CY, Wang YH, Hsu MH, Suk FM.
    Molecules; 2020 Jun 20; 25(12):. PubMed ID: 32575795
    [Abstract] [Full Text] [Related]

  • 38. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 39. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
    Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R.
    PLoS One; 2014 Mar 28; 9(9):e105919. PubMed ID: 25221930
    [Abstract] [Full Text] [Related]

  • 40. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
    Luszczak S, Simpson BS, Stopka-Farooqui U, Sathyadevan VK, Echeverria LMC, Kumar C, Costa H, Haider A, Freeman A, Jameson C, Ratynska M, Ben-Salha I, Sridhar A, Shaw G, Kelly JD, Pye H, Gately KA, Whitaker HC, Heavey S.
    Sci Rep; 2020 Sep 01; 10(1):14380. PubMed ID: 32873828
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.